Close Menu

More articles about Point-of-Care Testing

The point-of-care diagnostics firm tallied $9.6 million in revenues in the second quarter, besting analysts' consensus estimate of $8.8 million.

The firm said revenues fell because of delayed shipments of HIV self-tests and ongoing softness in the consumer genomics markets.

Expedeon will supply Sona Nanotech with colloidal gold technology for use in the development of multiplex lateral flow assays.

The German firm has developed a PCR technology that rapidly regulates temperature with so-called microcyclers diffused in the master mix solution.

Formerly known as Diassess, the Emeryville, California-based startup will use the funding to finance regulatory clearances and early commercialization.

In US influenza testing, providers see growth in placements within hospital emergency departments, physicians' offices, urgent care centers, and retail clinics.

The company also received a contract from the Henry M. Jackson Foundation for a separate sepsis test.

The research team said its nanofluidic system increased the proportion of nucleic acid and protein disease biomarkers a billionfold prior to detection.

The Singapore-based company will debut a system at AACC that performs real-time PCR flu A/B testing in less than 20 minutes for the cost of a lateral flow test. 

The Branford, Connecticut-based startup plans to seek US Food and Drug Administration clearance for and launch its instrument and first assays in 2021.

UK researchers said they are developing a commercial test that could enable sensitive detection of tuberculosis DNA in blood and provide an option to broaden screening. 

Rutgers researchers have developed a point-of-care tool that can rapidly assess the sensitivity of tumor cells to cancer drugs without staining or labeling.

The Dublin, Ireland-based company plans to launch its new instrument by the end of 2021 and will pursue CLIA waiver in the US.

Chembio said it will receive funding subject to satisfying milestones to develop a test that leverages its immunoassay platform and hand-held optical analyzer.

The firm said that its molecular diagnostics sales growth in the quarter was negatively impacted by non-governmental organization purchasing patterns in Africa.

Abbott said that its Afinion HbA1c assay used to diagnose diabetes could eventually be made available in physicians' offices through a CLIA waiver.

Treatment of Chagas disease can be lengthy and there is currently no available method to confirm whether a patient has been cured, according to the firm.

Nestlé Health said that employees of Prometheus are becoming employees of Precision IBD, with the exception of those working in its point-of-care diagnostic business.

One BioMed was spun out of Singapore's Agency for Science, Technology, and Research to  develop a point-of-care diagnostic platform for infectious disease.

Based in Austria, EuroLyser develops point-of-care testing devices and kits. ArchiMed also acquired EuroLab, EuroLyser's main distributor.

Pages